25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

      research-article
      1 , 2 , 2 , 3 , 2 , 4 , 5 , 6 , 7 ,   2 , 8 , 9 , 10 , 2 , 11 , 1 , 12 , 2 , 13 , 14 , 15 , 2 , 2 , 2 , 1
      (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab)
      The Journal of Infectious Diseases
      Oxford University Press
      AIDS-related opportunistic infections, HIV cohort studies, incidence, prophylaxis, combination antiretroviral therapy, CD4+ T-lymphocyte count, epidemiology

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background.  There are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immunodeficiency virus (HIV)–infected patients in care in the United States and Canada.

          Methods.  We studied HIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) during 2000–2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral therapy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, “person-years”) with 95% confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000–2003, 2004–2007, and 2008–2010.

          Results.  A total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation during 2000–2003, 2004–2007, and 2008–2010, respectively ( P trend<.001); the rates of most individual OIs decreased as well. During 2008–2010, the leading OIs included Pneumocystis jiroveci pneumonia, esophageal candidiasis, and disseminated Mycobacterium avium complex or Mycobacterium kansasii infection.

          Conclusions.  For HIV-infected persons in care during 2000–2010, rates of first OI were relatively low and generally declined over this time.

          Related collections

          Author and article information

          Journal
          J Infect Dis
          J. Infect. Dis
          jid
          jinfdis
          The Journal of Infectious Diseases
          Oxford University Press
          0022-1899
          1537-6613
          15 September 2016
          18 April 2016
          15 September 2017
          : 214
          : 6
          : 862-872
          Affiliations
          [1 ] Divisions of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
          [2 ] Johns Hopkins University, Baltimore, Maryland
          [3 ] Harvard University, Boston, Massachusetts
          [4 ] University of Calgary, Alberta, Canada
          [5 ] Kaiser Permanente Northern California, Oakland
          [6 ] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
          [7 ] Vanderbilt University Medical Center, Nashville, Tennessee
          [8 ] University of California–San Francisco
          [9 ] University of Alabama at Birmingham
          [10 ] Emory University, Atlanta, Georgia
          [11 ] British Columbia Centre for Excellence in HIV/AIDS, Vancouver
          [12 ] University of Toronto, Ontario, Canada
          [13 ] University of North Carolina at Chapel Hill
          [14 ] Hennepin County Medical Center, Minneapolis, Minnesota
          [15 ] Universidad Central del Caribe, Puerto Rico
          Author notes

          Presented in part: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 3–6 March 2014. Abstract 843.

          Correspondence: K. Buchacz, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E-45, Atlanta, GA 30329 ( acu7@ 123456cdc.gov ).
          Article
          PMC4996145 PMC4996145 4996145 jiw085
          10.1093/infdis/jiw085
          4996145
          27559122
          c2e98230-1376-4b51-ba9b-c9bf3a2ec811
          Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US
          History
          : 9 October 2015
          : 24 January 2016
          Funding
          Funded by: National Institutes of Health (NIH);
          Funded by: NIH;
          Award ID: U01AI069918
          Award ID: F31DA037788
          Award ID: G12MD007583
          Award ID: K01AI093197
          Award ID: K23EY013707
          Award ID: K24DA000432
          Award ID: K24AI065298
          Award ID: KL2TR000421
          Award ID: M01RR000052
          Award ID: N02CP055504
          Award ID: P30AI027757
          Award ID: P30AI027763
          Award ID: P30AI027767
          Award ID: P30AI036219
          Award ID: P30AI050410
          Award ID: P30AI094189
          Award ID: P30AI110527
          Award ID: P30MH62246
          Award ID: 01AA016893
          Award ID: R01CA165937
          Award ID: R01DA004334
          Award ID: R01DA011602
          Award ID: R01DA012568
          Award ID: R24AI067039
          Award ID: U01AA013566
          Award ID: U01AA020790
          Award ID: U01AI031834
          Award ID: U01AI034989
          Award ID: U01AI034993
          Award ID: U01AI034994
          Award ID: U01AI035004
          Award ID: U01AI035039
          Award ID: U01AI035040
          Award ID: U01AI035041
          Award ID: U01AI035042
          Award ID: U01AI037613
          Award ID: U01AI037984
          Award ID: U01AI038855
          Award ID: U01AI038858
          Award ID: U01AI042590
          Award ID: U01AI068634
          Award ID: U01AI068636
          Award ID: U01AI069432
          Award ID: U01AI069434
          Award ID: U01AI103390
          Award ID: U01AI103397
          Award ID: U01AI103401
          Award ID: U01AI103408
          Award ID: U01DA036935
          Award ID: U01HD032632
          Award ID: U10EY008057
          Award ID: U10EY008052
          Award ID: U10EY008067
          Award ID: U24AA020794
          Award ID: U54MD007587
          Award ID: UL1RR024131
          Award ID: UL1TR000004
          Award ID: UL1TR000083
          Award ID: UL1TR000454
          Award ID: UM1AI035043
          Award ID: Z01CP010214
          Award ID: Z01CP010176
          Funded by: National Cancer Institute;
          Categories
          Major Articles and Brief Reports
          HIV/AIDS
          Editor's choice

          prophylaxis,combination antiretroviral therapy,CD4+ T-lymphocyte count,epidemiology,AIDS-related opportunistic infections,HIV cohort studies,incidence

          Comments

          Comment on this article